newregime good luck see below plus obj are talking to others but best is go to the obj announ and read as many as u can to get the feel for the company also if u have the time the asx site under announ if u wanted to know from past years some relevant stuff there as obj has being working on this for a long time
Wednesday, 4 November 2009
OBJ ENTERS INTO MATERIALS TRANSFER AGREEMENT OBJ (ASX: OBJ) wishes to advise shareholders that it has entered into a Materials Transfer Agreement (MTA) with 3M Corporation of St Paul, Minnesota USA, for the evaluation of the Company’s eM‐patch® technologies as an approach to enhance transdermal drug delivery. 3M is an American multinational corporation with 79,000 employees operating in 60 countries generating global sales in excess of US$25 billion in 2008. The evaluation will be conducted by the 3M Drug Delivery Systems division which has been a leader in drug delivery for more than 50 years and has extensive expertise in toxicology, regulatory, manufacturing, quality assurance and operations. The Materials Transfer Agreement sets the parameters for an initial in vitro testing program to evaluate the performance of the eM‐patch® technology in conjunction with 3M drug delivery platforms and proprietary formulations. The evaluation program is expected to be completed by 1st February 2010. About OBJ Ltd OBJ Ltd is an early stage drug and cosmetic delivery company focused on the development and commercialization of transdermal and transmembrane patches and applicator technologies. OBJ develops low‐cost, high‐performance patch and applicator products and undertakes partner funded developments using the Company's dermaportation and eM‐patch® technologies. OBJ’s business focus is the development of new products for supply or licencing and providing feasibility assessments, patch formulations, testing and intellectual property development services to partner companies. About OBJ's Technologies OBJ's proprietary technologies utilise magnetic field and magnetic array processes to enhance the delivery of therapeutic and beneficial compounds. OBJ's technologies have been shown in multi‐centred university studies and independent commercial evaluations to enhance transdermal drug delivery of a wide a wide range of commercially significant drugs and peptides.
OBJ Price at posting:
2.4¢ Sentiment: Hold Disclosure: Held
(20min delay)